SCHEMBL10315917

SCHEMBL10315917

Nc1nc(-c2ccc(O)c(Br)c2)cs1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.59
MKNK1 Q9BUB5 1/20 0.59
MKNK2 Q9HBH9 1/20 0.59
MAPT P10636 8/20 0.57
RAB9A P51151 8/20 0.57
NPC1 O15118 6/20 0.57
SMN1; SMN2 Q16637 6/20 0.57
ALDH1A1 P00352 10/20 0.57
HPGD P15428 3/20 0.57
HK1 P19367 1/20 0.57
HKDC1 Q2TB90 1/20 0.57
KDM4E B2RXH2 5/20 0.54
NFKB1 P19838 2/20 0.54
NFKB2 Q00653 2/20 0.54
RELA Q04206 2/20 0.54
AR P10275 1/20 0.54
GFER P55789 1/20 0.54
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
TP53 P04637 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29276767 0.84 ALDH1A1 (0.67) LTA4HMKNK1MKNK2MAPTRAB9A
SCHEMBL10315988 0.80 LTA4H (0.59) LTA4HMKNK1MKNK2MAPTRAB9A
SCHEMBL10087446 0.80 ALDH1A1 (0.61) LTA4HMKNK1MKNK2MAPTRAB9A
SCHEMBL16345828 0.80 RAB9A (0.57) LTA4HMKNK1MKNK2MAPTRAB9A
SCHEMBL474270 0.80 MPL (0.63) LTA4HMKNK1MKNK2MAPTRAB9A
SCHEMBL4704845 0.80 LTA4H (0.59) LTA4HMKNK1MKNK2MAPTRAB9A
SCHEMBL10200395 0.80 LTA4H (0.59) LTA4HMKNK1MKNK2MAPTRAB9A
SCHEMBL10315892 0.80 LTA4H (0.59) LTA4HMKNK1MKNK2MAPTRAB9A
SCHEMBL16346205 0.77 RAB9A (0.57) LTA4HMKNK1MKNK2MAPTRAB9A
SCHEMBL16346609 0.77 RAB9A (0.57) LTA4HMKNK1MKNK2MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178766-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178766-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS TRPA1, TRPV1, TRPC3 LTA4H 234/4885MKNK1 1595/4885MKNK2 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.